S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
52-week Low Names To Tip The Upside Scale In Your Favor
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
3 Reasons This Sleeping Giant Is About To Wake Up
KB Home Price Weakness is a Signal to Buy this Cash Machine
BREAKING: Tiny biotech successfully treats blindness (Ad)
Things to know about California's new proposed rules for insurance companies
MarketBeat Week in Review – 9/18 - 9/22
66,000% upside on tiny biotech? (Ad)
How major US stock indexes fared Friday, 9/22/2023
Closing prices for crude oil, gold and other commodities
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
52-week Low Names To Tip The Upside Scale In Your Favor
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
3 Reasons This Sleeping Giant Is About To Wake Up
KB Home Price Weakness is a Signal to Buy this Cash Machine
BREAKING: Tiny biotech successfully treats blindness (Ad)
Things to know about California's new proposed rules for insurance companies
MarketBeat Week in Review – 9/18 - 9/22
66,000% upside on tiny biotech? (Ad)
How major US stock indexes fared Friday, 9/22/2023
Closing prices for crude oil, gold and other commodities
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
52-week Low Names To Tip The Upside Scale In Your Favor
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
3 Reasons This Sleeping Giant Is About To Wake Up
KB Home Price Weakness is a Signal to Buy this Cash Machine
BREAKING: Tiny biotech successfully treats blindness (Ad)
Things to know about California's new proposed rules for insurance companies
MarketBeat Week in Review – 9/18 - 9/22
66,000% upside on tiny biotech? (Ad)
How major US stock indexes fared Friday, 9/22/2023
Closing prices for crude oil, gold and other commodities
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
52-week Low Names To Tip The Upside Scale In Your Favor
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
3 Reasons This Sleeping Giant Is About To Wake Up
KB Home Price Weakness is a Signal to Buy this Cash Machine
BREAKING: Tiny biotech successfully treats blindness (Ad)
Things to know about California's new proposed rules for insurance companies
MarketBeat Week in Review – 9/18 - 9/22
66,000% upside on tiny biotech? (Ad)
How major US stock indexes fared Friday, 9/22/2023
Closing prices for crude oil, gold and other commodities
NASDAQ:IART

Integra LifeSciences (IART) Stock Forecast, Price & News

$38.56
-0.16 (-0.41%)
(As of 09/22/2023 ET)
Compare
Today's Range
$38.52
$39.06
50-Day Range
$38.46
$45.97
52-Week Range
$37.36
$60.69
Volume
503,444 shs
Average Volume
608,287 shs
Market Capitalization
$3.14 billion
P/E Ratio
24.56
Dividend Yield
N/A
Price Target
$47.29

Integra LifeSciences MarketRank™ Forecast

Analyst Rating
Reduce
1.86 Rating Score
Upside/​Downside
22.6% Upside
$47.29 Price Target
Short Interest
Healthy
3.64% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.50
Upright™ Environmental Score
News Sentiment
0.46mentions of Integra LifeSciences in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
11.15%
From $3.14 to $3.49 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.34 out of 5 stars

Medical Sector

267th out of 968 stocks

Surgical & Medical Instruments Industry

31st out of 92 stocks


IART stock logo

About Integra LifeSciences (NASDAQ:IART) Stock

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

IART Price History

IART Stock News Headlines

66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
18 Highest Paying Countries for Neurosurgeons
Integra Lifesciences (IART) Receives a Buy from JMP Securities
See More Headlines
Receive IART Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Integra LifeSciences and its competitors with MarketBeat's FREE daily newsletter.

IART Company Calendar

Last Earnings
7/26/2023
Today
9/23/2023
Next Earnings (Estimated)
10/25/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:IART
CUSIP
45798520
Employees
3,722
Year Founded
1989

Price Target and Rating

Average Stock Price Forecast
$47.29
High Stock Price Forecast
$60.00
Low Stock Price Forecast
$39.00
Forecasted Upside/Downside
+22.6%
Consensus Rating
Reduce
Rating Score (0-4)
1.86
Research Coverage
7 Analysts

Profitability

Net Income
$180.55 million
Pretax Margin
10.13%

Debt

Sales & Book Value

Annual Sales
$1.56 billion
Cash Flow
$4.83 per share
Book Value
$21.57 per share

Miscellaneous

Free Float
77,981,000
Market Cap
$3.14 billion
Optionable
Optionable
Beta
1.20

Social Links

10 Best Stocks to Own in 2023 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Jan De Witte (Age 59)
    Pres, CEO & Director
    Comp: $1.82M
  • Mr. Eric Ian SchwartzMr. Eric Ian Schwartz (Age 54)
    Exec. VP, Chief Legal Officer & Sec.
    Comp: $847.2k
  • Mr. Robert T. Davis Jr. (Age 64)
    Exec. VP & Pres of Tissue Technologies
    Comp: $781.23k
  • Mr. Michael J. McBreenMr. Michael J. McBreen (Age 57)
    Exec. VP & Pres of Codman Specialty Surgical
    Comp: $780.77k
  • Ms. Lea Daniels Knight
    Exec. VP & CFO
  • Mr. Stephen Leonard (Age 61)
    Corp. VP of Global Operations & Supply Chain
  • Mr. Jeffrey A. MosebrookMr. Jeffrey A. Mosebrook (Age 47)
    Sr. VP & PAO
  • Mr. Mathieu Aussermeier
    VP of Corp. Fin., Investor Relations & Treasurer
  • Dr. Kenneth E. Burhop Ph.D. (Age 69)
    Corp. VP & Chief Scientific Officer
  • Mr. William Compton
    Chief Information Officer & Corp. VP













IART Stock - Frequently Asked Questions

Should I buy or sell Integra LifeSciences stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Integra LifeSciences in the last twelve months. There are currently 3 sell ratings, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" IART shares.
View IART analyst ratings
or view top-rated stocks.

What is Integra LifeSciences' stock price forecast for 2023?

7 Wall Street analysts have issued 1-year target prices for Integra LifeSciences' stock. Their IART share price forecasts range from $39.00 to $60.00. On average, they predict the company's stock price to reach $47.29 in the next year. This suggests a possible upside of 22.6% from the stock's current price.
View analysts price targets for IART
or view top-rated stocks among Wall Street analysts.

How have IART shares performed in 2023?

Integra LifeSciences' stock was trading at $56.07 at the beginning of 2023. Since then, IART shares have decreased by 31.2% and is now trading at $38.56.
View the best growth stocks for 2023 here
.

Are investors shorting Integra LifeSciences?

Integra LifeSciences saw a drop in short interest during the month of August. As of August 31st, there was short interest totaling 2,570,000 shares, a drop of 9.2% from the August 15th total of 2,830,000 shares. Based on an average trading volume of 654,400 shares, the days-to-cover ratio is presently 3.9 days. Currently, 3.6% of the shares of the company are sold short.
View Integra LifeSciences' Short Interest
.

When is Integra LifeSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 25th 2023.
View our IART earnings forecast
.

How were Integra LifeSciences' earnings last quarter?

Integra LifeSciences Holdings Co. (NASDAQ:IART) released its quarterly earnings data on Wednesday, July, 26th. The life sciences company reported $0.71 EPS for the quarter, topping analysts' consensus estimates of $0.57 by $0.14. The life sciences company earned $381.30 million during the quarter, compared to analysts' expectations of $388.79 million. Integra LifeSciences had a trailing twelve-month return on equity of 15.60% and a net margin of 8.49%. The business's revenue for the quarter was down 4.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.82 earnings per share.

When did Integra LifeSciences' stock split?

Integra LifeSciences shares split on Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly created shares were issued to shareholders after the market closes on Wednesday, December 21st 2016. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What guidance has Integra LifeSciences issued on next quarter's earnings?

Integra LifeSciences issued an update on its FY 2023 earnings guidance on Thursday, July, 27th. The company provided earnings per share (EPS) guidance of $3.10-$3.18 for the period, compared to the consensus EPS estimate of $3.12. The company issued revenue guidance of $1.55 billion-$1.56 billion, compared to the consensus revenue estimate of $1.56 billion.

What is Peter J. Arduini's approval rating as Integra LifeSciences' CEO?

173 employees have rated Integra LifeSciences Chief Executive Officer Peter J. Arduini on Glassdoor.com. Peter J. Arduini has an approval rating of 74% among the company's employees.

What other stocks do shareholders of Integra LifeSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Integra LifeSciences investors own include Boeing (BA), NVIDIA (NVDA), AbbVie (ABBV), Adobe (ADBE), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Marvell Technology (MRVL), Alexion Pharmaceuticals (ALXN) and Abbott Laboratories (ABT).

What is Integra LifeSciences' stock symbol?

Integra LifeSciences trades on the NASDAQ under the ticker symbol "IART."

Who are Integra LifeSciences' major shareholders?

Integra LifeSciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Shaolin Capital Management LLC (0.00%), Champlain Investment Partners LLC (4.79%), Capital Research Global Investors (4.00%), Alliancebernstein L.P. (3.53%), Clearbridge Investments LLC (3.39%) and Cooke & Bieler LP (3.37%). Insiders that own company stock include Eric Schwartz, Glenn Coleman, Jeffrey Mosebrook, Lisa Evoli, Michael J Mcbreen, Raymond G Murphy, Stuart Essig, Tru St Partnership, LP and Witte Jan De.
View institutional ownership trends
.

How do I buy shares of Integra LifeSciences?

Shares of IART stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Integra LifeSciences' stock price today?

One share of IART stock can currently be purchased for approximately $38.56.

How much money does Integra LifeSciences make?

Integra LifeSciences (NASDAQ:IART) has a market capitalization of $3.14 billion and generates $1.56 billion in revenue each year. The life sciences company earns $180.55 million in net income (profit) each year or $1.57 on an earnings per share basis.

How many employees does Integra LifeSciences have?

The company employs 3,722 workers across the globe.

Does Integra LifeSciences have any subsidiaries?
The following companies are subsidiares of Integra LifeSciences: ACell Inc, ACell Inc., Arkis BioSciences, Arkis Biosciences Inc., Ascension Orthopedics Inc., Ascension Orthopedics Limited, BIMECO Inc., BioD LLC, BioDlogics LLC, BioRecovery LLC, CardioDyne Inc., Cathtec Incorporated, Caveangle Limited, Codman Neuro, Confluent Surgical, Confluent Surgical Inc., Derma First Aid Products Inc., Derma Sciences, Derma Sciences Canada Inc., Derma Sciences Europe Limited, Derma Sciences Inc., EndoSolutions Inc., Fiber Imaging Technologies Inc., GMS Gesellschaft für medizinische Sondentechnik mbH, ILS Financing (Ireland) Limited, ILS Financing Corporation, ILS Services Switzerland Ltd., ILS Surgical Investments LLC, INS Sweden AB, Integra Burlington MA Inc., Integra CI Inc., Integra Canada ULC, Integra Euro Holdings Inc., Integra France Holdings SAS, Integra German Holdings GmbH, Integra GmbH, Integra Japan K.K., Integra LS (Benelux) NV, Integra LS Mexico S. DE R. L. DE C.V., Integra LifeSciences (Canada) Holdings Inc., Integra LifeSciences (Ireland) Limited, Integra LifeSciences (Shanghai) Co. Ltd., Integra LifeSciences Austria GmbH, Integra LifeSciences Brazil Ltda., Integra LifeSciences Corporation, Integra LifeSciences Enterprises LLLP, Integra LifeSciences Financing (Cyprus) Limited, Integra LifeSciences Italy S.r.l., Integra LifeSciences Middle East FZ-LLC, Integra LifeSciences Production Corporation, Integra LifeSciences Sales LLC, Integra LifeSciences Services (France) SAS, Integra LifeSciences Shared Services (Ireland) Limited, Integra LifeSciences Singapore Pte. Ltd., Integra LifeSciences Spain S.L., Integra LifeSciences Switzerland Sárl, Integra Luxtec Inc., Integra ME GmbH, Integra MicroFrance SAS, Integra NeuroSciences (International) Inc., Integra NeuroSciences Holdings (UK) Limited, Integra NeuroSciences Holdings B.V., Integra NeuroSciences Implants (France) SAS, Integra NeuroSciences Limited, Integra Neurosciences, Integra Neurosciences Pty Ltd. (AUS), Integra Neurosciences Pty Ltd. (NZ), Integra Receivables LLC, Integra Sales Inc., Integra Selector LLC, Integra Switzerland Holdings Sarl, Integra York PA Inc., IsoTis NV, IsoTis T.E. Facility B.V., J. Jamner Surgical Instruments Inc., Jarit GmbH, Kinetikos Medical, Koby Ventures II L.P. dba Metasurg, LXU Healthcare Inc. - Medical Specialty Products, MedEfficiency Inc., Medtronic Xomed Instrumentation SAS, Miltex, Minnesota Scientific Inc., Nantong Derma Medical Products Co. Ltd., Newdeal Inc., Newdeal SAS, Omni-Tract, Precise Dental Holding Corp., Precise Dental Internacional S.A. de C.V., Precise Dental Products Ltd., Precision Dental International Inc., Rebound Therapeutics, Rebound Therapeutics Corporation, Spembly Cryosurgery Limited, Spembly Medical Limited, TEI Biosciences (UK) Limited, TEI Biosciences Inc., TEI Biosciences Inc., TEI Medical Inc., TGX Medical Systems, TGX Medical Systems LLC, Tarsus Medical Inc., Tarsus Medical Inc., Tekmed Instruments S.p.A, Theken Disc, Theken Spine, and Therics.
Read More
How can I contact Integra LifeSciences?

Integra LifeSciences' mailing address is 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536. The official website for the company is www.integralife.com. The life sciences company can be reached via phone at (609) 275-0500, via email at ir@integralife.com, or via fax at 609-750-4277.

This page (NASDAQ:IART) was last updated on 9/23/2023 by MarketBeat.com Staff

My Account -